Maria Del Ben

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7755345/publications.pdf

Version: 2024-02-01

96 papers 3,541 citations

35 h-index 149698 56 g-index

96 all docs 96 docs citations

96 times ranked 5478 citing authors

#	Article	IF	CITATIONS
1	Statin liver safety in nonâ€alcoholic fatty liver disease: A systematic review and metanalysis. British Journal of Clinical Pharmacology, 2022, 88, 441-451.	2.4	28
2	Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines, 2022, 10, 720.	3.2	5
3	Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. Nutrients, 2022, 14, 1127.	4.1	22
4	High Compliance to Mediterranean Diet Associates with Lower Platelet Activation and Liver Collagen Deposition in Patients with Nonalcoholic Fatty Liver Disease. Nutrients, 2022, 14, 1209.	4.1	5
5	Extra Virgin Olive Oil Reduces Gut Permeability and Metabolic Endotoxemia in Diabetic Patients. Nutrients, 2022, 14, 2153.	4.1	11
6	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the realâ€life setting: the PROSISA Study. Journal of Internal Medicine, 2021, 290, 116-128.	6.0	21
7	Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. Clinical Gastroenterology and Hepatology, 2021, 19, 2683-2684.	4.4	6
8	Sex-Related Differences in the Association between Metabolic Syndrome and Gallstone Disease. International Journal of Environmental Research and Public Health, 2021, 18, 1958.	2.6	3
9	Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?. Digestive and Liver Disease, 2021, 53, 383-384.	0.9	7
10	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Internal and Emergency Medicine, 2021, 16, 2063-2068.	2.0	5
11	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. Pharmacological Research, 2021, 165, 105418.	7.1	21
12	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. International Journal of Molecular Sciences, 2021, 22, 7193.	4.1	26
13	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. International Journal of Environmental Research and Public Health, 2021, 18, 8993.	2.6	10
14	The challenge of cardiovascular prevention in NAFLD. The Lancet Gastroenterology and Hepatology, 2021, 6, 877-878.	8.1	5
15	Prevention and management of type II diabetes chronic complications: the role of polyphenols (Mini-Review). Current Medicinal Chemistry, 2021, 28, .	2.4	3
16	Chocolate enriched by extra virgin olive oil improves endothelial function and oxidative stress in patients with diabetes. Nutrition, 2021, 90, 111270.	2.4	4
17	Commentary on "Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial― Hepatobiliary Surgery and Nutrition, 2021, 10, 699-701.	1.5	O
18	Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines, 2021, 9, 1370.	3.2	6

#	Article	IF	CITATIONS
19	Oxidative stress mediated platelet activation in patients with congenital analbuminemia: Effect of albumin infusion. Journal of Thrombosis and Haemostasis, 2021, 19, 3090-3094.	3.8	4
20	Oleuropein-enriched chocolate by extra virgin olive oil blunts hyperglycaemia in diabetic patients: Results from a one-time 2-hour post-prandial cross over study. Clinical Nutrition, 2020, 39, 2187-2191.	5.0	13
21	Nonalcoholic Fatty Liver Disease and Fibrosis AssociatedÂWith Increased Risk of Cardiovascular EventsÂinÂaÂProspective Study. Clinical Gastroenterology and Hepatology, 2020, 18, 2324-2331.e4.	4.4	136
22	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. Mayo Clinic Proceedings, 2020, 95, 513-520.	3.0	11
23	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology, 2020, 72, 470-485.	7.3	203
24	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients, 2020, 12, 2762.	4.1	89
25	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines, 2020, 8, 625.	3.2	21
26	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 2020, 12, 1732.	4.1	33
27	A systematic review on the association between obstructive sleep apnea and chronic kidney disease. Sleep Medicine Reviews, 2020, 53, 101337.	8.5	18
28	Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2020, 11, e00116.	2.5	10
29	Association between non-alcoholic fatty liver disease and obstructive sleep apnea. World Journal of Gastroenterology, 2020, 26, 2669-2681.	3.3	32
30	Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil. European Journal of Nutrition, 2019, 58, 843-851.	3.9	25
31	Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?. Antioxidants and Redox Signaling, 2019, 30, 1325-1330.	5.4	20
32	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 2301-2308.	3.9	15
33	Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1087-1094.	2.6	19
34	Blueberry-Based Meals for Obese Patients with Metabolic Syndrome: A Multidisciplinary Metabolomic Pilot Study. Metabolites, 2019, 9, 138.	2.9	17
35	Statins and nonâ€elcoholic fatty liver disease. Liver International, 2019, 39, 1787-1787.	3.9	3
36	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. World Journal of Gastroenterology, 2019, 25, 4172-4180.	3.3	23

#	Article	IF	Citations
37	Long-term prediction of adherence to continuous positive air pressure therapy for the treatment of moderate/severe obstructive sleep apnea syndrome. Sleep Medicine, 2018, 43, 66-70.	1.6	66
38	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Scientific Reports, 2018, 8, 3702.	3.3	59
39	Role of NADPH oxidase-2 and oxidative stress in children exposed to passive smoking. Thorax, 2018, 73, 986-988.	5.6	16
40	Severity of OSAS, CPAP and cardiovascular events: A followâ€up study. European Journal of Clinical Investigation, 2018, 48, e12908.	3.4	31
41	Response to Duret et al American Journal of Gastroenterology, 2018, 113, 775-776.	0.4	0
42	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.8	48
43	Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2018, 7, 378.	2.4	36
44	Passive Smoking Exacerbates Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Isoform 2–Induced Oxidative Stress and Arterial Dysfunction in Children with Persistent Allergic Rhinitis. Journal of Pediatrics, 2018, 202, 252-257.	1.8	9
45	Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. International Journal of Molecular Sciences, 2018, 19, 603.	4.1	7
46	Extra virgin olive oil improves post-prandial glycemic and lipid profile in patients with impaired fasting glucose. Clinical Nutrition, 2017, 36, 782-787.	5.0	50
47	The role of nutraceuticals for the treatment of nonâ€alcoholic fatty liver disease. British Journal of Clinical Pharmacology, 2017, 83, 88-95.	2.4	74
48	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis, 2017, 262, 179-184.	0.8	19
49	ADHERENCE TO MEDITERRANEAN DIET AND NON ALCOHOLIC FATTY LIVER DISEASE: IMPACT ON METABOLIC PROFILE. Journal of the American College of Cardiology, 2017, 69, 1868.	2.8	0
50	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically-versus genetically-driven excess fat hepatic storage. Atherosclerosis, 2017, 257, 232-239.	0.8	39
51	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. American Journal of Gastroenterology, 2017, 112, 1832-1839.	0.4	109
52	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
53	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
54	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. Internal and Emergency Medicine, 2017, 12, 1159-1165.	2.0	16

#	Article	IF	Citations
55	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. Scientific Reports, 2017, 7, 15756.	3.3	45
56	Lowâ€grade endotoxemia and platelet activation in cirrhosis. Hepatology, 2017, 65, 571-581.	7.3	107
57	Chronic granulomatous disease as an SOS call for multicenter cooperative effort to prevent infections. Annals of Allergy, Asthma and Immunology, 2016, 117, 285-289.	1.0	7
58	Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with TypeÂ2 diabetes. Clinical Science, 2016, 130, 1753-1762.	4.3	16
59	No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine, 2016, 14, 92.	5 . 5	130
60	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Internal and Emergency Medicine, 2016, 11, 199-204.	2.0	41
61	Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. International Journal of Molecular Sciences, 2015, 16, 28014-28021.	4.1	18
62	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World Journal of Hepatology, 2015, 7, 1325.	2.0	152
63	Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. Chest, 2015, 147, 1644-1650.	0.8	59
64	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. Europace, 2015, 17, 1223-1228.	1.7	13
65	New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials. Internal and Emergency Medicine, 2015, 10, 499-506.	2.0	19
66	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2015, 47, 4-11.	0.9	121
67	Relation of Nonalcoholic Fatty Liver Disease and Framingham Risk Score to Flow-Mediated Dilation in Patients With Cardiometabolic Risk Factors. American Journal of Cardiology, 2015, 115, 1402-1406.	1.6	24
68	Endothelial dysfunction and oxidative stress in children with sleep disordered breathing: Role of NADPH oxidase. Atherosclerosis, 2015, 240, 222-227.	0.8	49
69	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. Clinical and Translational Gastroenterology, 2015, 6, e113.	2.5	25
70	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. EBioMedicine, 2015, 2, 750-754.	6.1	51
71	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. International Journal of Cardiology, 2015, 201, 513-516.	1.7	57
72	Modern approach to the clinical management of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 8341.	3.3	61

#	Article	IF	CITATIONS
73	Role of platelets in NOX2 activation mediated by TNF $\hat{l}\pm$ in heart failure. Internal and Emergency Medicine, 2014, 9, 179-185.	2.0	15
74	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. Digestive and Liver Disease, 2014, 46, 632-638.	0.9	11
75	NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology, 2014, 14, 81.	2.0	71
76	LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism. Atherosclerosis, 2014, 237, 108-116.	0.8	91
77	Strong interplay between metabolic syndrome, obstructive sleep apnoea, oxidative stress and arterial dysfunction. Sleep and Breathing, 2013, 18, 223-4.	1.7	2
78	Comment on "Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property― Digestive and Liver Disease, 2013, 45, 81-82.	0.9	1
79	Antithrombotic drugs in acutely ill medical patients: review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux. Clinical Practice (London, England), 2013, 10, 615-627.	0.1	3
80	Obesity and Hypercholesterolemia are Associated with NOX2 Generated Oxidative Stress and Arterial Dysfunction. Journal of Pediatrics, 2012, 161, 1004-1009.	1.8	74
81	Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Internal and Emergency Medicine, 2012, 7, 291-296.	2.0	27
82	Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. BMC Pulmonary Medicine, 2012, 12, 36.	2.0	74
83	Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Internal and Emergency Medicine, 2012, 7, 219-227.	2.0	42
84	Obstructive sleep apnoea syndrome and the metabolic syndrome in an internal medicine setting. European Journal of Internal Medicine, 2010, 21, 191-195.	2.2	43
85	Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. Free Radical Biology and Medicine, 2007, 43, 853-859.	2.9	60
86	Alpha-Linolenic Acid–Rich Wheat Germ Oil Decreases Oxidative Stress and CD40 Ligand in Patients With Mild Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2577-2578.	2.4	53
87	Congenital Analbuminemia attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene. Clinical Chemistry, 2005, 51, 1256-1258.	3.2	26
88	CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. Journal of the American College of Cardiology, 2005, 45, 35-42.	2.8	56
89	Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia. American Journal of Medicine, 2004, 117, 803-804.	1.5	14
90	Nonâ€alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 588-594.	2.8	149

#	Article	IF	CITATION
91	Attitudes and approach to cardiovascular risk factors in Italy: results of an electronic questionnaire survey. Public Health, 2003, 117, 242-249.	2.9	6
92	Recurrence of insulin resistant metabolic syndrome following liver transplantation. European Journal of Gastroenterology and Hepatology, 2003, 15, 99-102.	1.6	14
93	A late complication of pelvic radiotherapy: leiomyosarcoma of the rectum. Report of a case and review of the literature. Hepato-Gastroenterology, 2003, 50, 1933-6.	0.5	6
94	Role of genetic variation at the Apo Al-CIII-AIV gene cluster in determining plasma Apo Al levels in boys and girls. Genetic Epidemiology, 1993, 10, 113-122.	1.3	58
95	Apolipoprotein E polymorphism and plasma lipid, lipoprotein, and apolipoprotein levels in Italian children. Genetic Epidemiology, 1991, 8, 389-398.	1.3	33
96	Apolipoprotein B amino acid 3611 substitution from arginine to glutamine creates the Ag (h/i) epitope: the polymorphism is not associated with differences in serum cholesterol and apolipoprotein B levels. Human Genetics, 1989, 82, 322-6.	3.8	40